Comparative Study of Remimazolam and Midazolam During Sedated Upper Gastrointestinal Endoscopy: A Propensity Score Matching Analysis
- PMID: 39834907
- PMCID: PMC11744072
- DOI: 10.1002/jgh3.70100
Comparative Study of Remimazolam and Midazolam During Sedated Upper Gastrointestinal Endoscopy: A Propensity Score Matching Analysis
Abstract
Aim: This study aimed to compare the use of remimazolam and midazolam in upper gastrointestinal endoscopy in Japan as a sub-analysis of data from an investigator-initiated clinical trial of remimazolam.
Methods and results: Patients in two groups were matched using propensity score matching. We evaluated the time from the end of the gastrointestinal endoscopy until discharge, the time from the end of the procedure until awakening, and adverse events. Overall, 36 participants from the clinical trial population who underwent upper gastrointestinal endoscopy using remimazolam and 199 patients who underwent the procedure with midazolam during the same period were included in this study. Following propensity score matching, 34 patients in both groups were matched. The median time from the end of the procedure until awakening was 27.0 min (23.0-40.5 min) in the midazolam group (Group M) and 0 min (0-5.0 min) in the remimazolam group (Group R); the median time from the end of the upper gastrointestinal endoscopy until discharge was 39.0 min (35.0-52.5 min) in Group M and 5.0 min (0-5.0 min) in Group R (p < 0.01). Reported adverse events were hypotension and hypoxemia in one patient in Group R.
Conclusion: Compared with midazolam, remimazolam significantly shortened the time to patient awakening and duration until the patient could leave the endoscopy room. Trial Registration: The main study (REM-IICT JP1) is registered with the Japan Registry of Clinical Trails: jRCT2031200360.
Keywords: endoscopy; gastrointestinal; midazolam; propensity score; remimazolam.
© 2025 The Author(s). JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
Comparison of remimazolam and midazolam for sedation during colonoscopy in Japanese patients: A propensity score matching analysis.DEN Open. 2024 Jul 23;5(1):e412. doi: 10.1002/deo2.412. eCollection 2025 Apr. DEN Open. 2024. PMID: 39050143 Free PMC article.
-
Usefulness and safety of remimazolam in upper gastrointestinal endoscopy: A comparative study between elderly and non-elderly patients.DEN Open. 2025 Jan 16;5(1):e70057. doi: 10.1002/deo2.70057. eCollection 2025 Apr. DEN Open. 2025. PMID: 39822951 Free PMC article.
-
Efficacy and safety of remimazolam tosylate for sedation during upper gastrointestinal endoscopy: study protocol for a multicenter randomized controlled trial.Trials. 2022 Dec 12;23(1):995. doi: 10.1186/s13063-022-06935-0. Trials. 2022. PMID: 36510290 Free PMC article.
-
The comparison of remimazolam and midazolam for the sedation of gastrointestinal endoscopy: a meta-analysis of randomized controlled studies.Afr Health Sci. 2022 Jun;22(2):384-391. doi: 10.4314/ahs.v22i2.44. Afr Health Sci. 2022. PMID: 36407397 Free PMC article.
-
Efficacy and Safety of Remimazolam in Endoscopic Sedation-A Systematic Review and Meta-Analysis.Front Med (Lausanne). 2021 Jul 26;8:655042. doi: 10.3389/fmed.2021.655042. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34381792 Free PMC article.
References
-
- Siegel R., Naishadham D., and Jemal A., “Cancer Statistics, 2012,” CA: A Cancer Journal for Clinicians 62 (2012): 10–29. - PubMed
-
- Park C. H., Park S. W., Jung J. H., et al., “Clinical Outcomes of Sedation During Emergency Endoscopic Band Ligation for Variceal Bleeding: Multicenter Cohort Study,” Digestive Endoscopy 32 (2020): 894–903. - PubMed
-
- McQuaid K. R. and Laine L., “A Systematic Review and Meta‐Analysis of Randomized, Controlled Trials of Moderate Sedation for Routine Endoscopic Procedures,” Gastrointestinal Endoscopy 67 (2008): 910–923. - PubMed
LinkOut - more resources
Full Text Sources